Compare BIIB & TTWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIIB | TTWO |
|---|---|---|
| Founded | 1978 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 43.2B |
| IPO Year | 1991 | 1997 |
| Metric | BIIB | TTWO |
|---|---|---|
| Price | $174.28 | $241.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 20 |
| Target Price | $177.40 | ★ $269.25 |
| AVG Volume (30 Days) | ★ 2.0M | 1.4M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 10.97 | N/A |
| Revenue | ★ $10,065,900,000.00 | $6,219,900,000.00 |
| Revenue This Year | $3.61 | $17.42 |
| Revenue Next Year | N/A | $38.29 |
| P/E Ratio | $15.86 | ★ N/A |
| Revenue Growth | 4.77 | ★ 13.98 |
| 52 Week Low | $110.04 | $177.35 |
| 52 Week High | $185.17 | $264.79 |
| Indicator | BIIB | TTWO |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 44.69 |
| Support Level | $169.24 | $245.99 |
| Resistance Level | $180.79 | $250.18 |
| Average True Range (ATR) | 5.36 | 4.16 |
| MACD | -1.56 | 0.27 |
| Stochastic Oscillator | 33.70 | 41.34 |
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Take-Two is one of the largest global developers and publishers of video games, with labels including Rockstar, 2K, and Zynga. Grand Theft Auto is the firm's biggest franchise, accounting for about 30% of total sales for the past decade. NBA 2K is the industry's dominant basketball video game, with Take-Two releasing a new version annually. Other notable franchises include Red Dead Redemption, Borderlands, and Civilization. Typically, more than three-fourths of the firm's sales are from in-game spending, with the remainder coming from initial game sales. Since acquiring Zynga in 2022, mobile makes up about half of total sales.